Dapsone for chronic autoimmune thrombocytopenic purpura: a report of 66 cases.
Sixty-six adults with chronic autoimmune thrombocytopenic purpura AITP and platelet count <50 x 10(9)/l were treated with dapsone (75-100 mg orally). A response was observed in 33 patients. The median duration of treatment required to obtain a response was 21 d (range 8-90). The median maximal platelet count on treatment was 130 x 10(9)/l (range 71-355). Dapsone was continued in 20/33 responders for a median of 12.5 months (range 1-48) and the response persisted in 19. Treatment was intentionally withdrawn in the other 13 responders and thrombocytopenia immediately recurred in 12. Reversible side-effects required cessation of treatment in seven patients. These results demonstrate that dapsone is an effective, inexpensive, and well-tolerated treatment for chronic AITP.
Godeau
B
B
Laboratoire d'Immunologie Leuco-plaquettaire, Hôpital Henri Mondor, Créteil, France.
Durand
J M
JM
Roudot-Thoraval
F
F
Tennezé
A
A
Oksenhendler
E
E
Kaplanski
G
G
Schaeffer
A
A
Bierling
P
P
D000328:Adult; D002908:Chronic Disease; D003622:Dapsone / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010976:Platelet Count / Q000187:drug effects; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy*; D016896:Treatment Outcome
D003622:Dapsone